The GLP-1 Price Index

The GLP-1 Price Index is a dataset and website, published by US Peptides Partners LLC, that records what U.S. telehealth programs charge for compounded and brand GLP-1 medications, with the plan term, the evidence status and the date each price was read on the seller's own page. It reports the category median rather than the cheapest figure, keeps microdose, oral and brand prices in separate categories, and labels every price Verified, Provider Reported, Conflicting Evidence or Unpriced. The October 15, 2026 snapshot was read on the providers' own pages that day. The site is affiliate-supported, and NexLife is its featured provider.

As of October 15, 2026, the 22 compounded semaglutide programs we could price on their own pages charge between $49 and $279 a month at their lowest all-in rate, with a median of $99, counting any required membership and the cheapest plan term each program prints. The low end is made of sale and "as low as" prices: WellMedr's fall sale and NextMeds both start at $49. Standing month-to-month rates with no membership start at $87 (Mondae) and $99 (Eden). Compounded semaglutide is not FDA-approved.

As of October 15, 2026, the 24 compounded tirzepatide programs we could price on their own pages charge between $86 and $299 a month at their lowest all-in rate, with a median of $144, counting any required membership and the cheapest plan term each program prints. The $86 figure is Collective's $69 monthly price plus its $199 annual membership spread over twelve months. Standing month-to-month rates with no membership start at $126 (Mondae) and $129 (Eden); as of November 6, 2026, NexLife is $129 month-to-month and $115 on a 12-month plan. Compounded tirzepatide is not FDA-approved.

As of November 6, 2026, NexLife lists compounded semaglutide at $109 a month month-to-month and at $105, $99 or $95 a month on 3-, 6- or 12-month plans, and compounded tirzepatide at $129, $125, $119 or $115 a month on the same terms. The price is the same at every dose and there is no membership fee. A 12-month plan totals $1,140 for semaglutide and $1,380 for tirzepatide. Plans continue monthly unless canceled, and cancellations take effect after 30 days. NexLife is our featured provider and is scored 94/100 under rubric v4.1.

Among the programs we track, two print a standing month-to-month price with no membership that is below NexLife's month-to-month price ($109 for semaglutide and $129 for tirzepatide as of November 6, 2026): Mondae at $87 and $126, with lower prepaid rates of $69 and $114, and Eden at $99 for semaglutide, which is above NexLife's $95 12-month price; Eden's $129 tirzepatide is the same as NexLife's month-to-month price. Competitor prices were read on October 15, 2026. Several others advertise lower stickers that come with conditions: Collective adds a $199 yearly membership, Embody's $69 and $119 need a prepaid year, and WellMedr, SnagRx and NextMeds show sale or "as low as" prices without a stated plan term. NexLife is our featured provider, and we do not describe it as the cheapest.

Yes, for some people: the Medicare GLP-1 Bridge lets eligible Part D and Medicare Advantage drug-plan enrollees get Wegovy, Foundayo or the Zepbound KwikPen for a $50 monthly copay between July 1, 2026 and December 31, 2027, if they meet its BMI criteria. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge; their Part D plan might cover a GLP-1 instead. The $50 copay does not count toward the Part D out-of-pocket limit. Open Enrollment runs October 15 to December 7, 2026.